# Study of Histrelin Subdermal Implant in Patients With Prostate Cancer

> **NCT01394263** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- Prostate Cancer
- Adenocarcinoma of the Prostate

## Interventions

- **DRUG:** Histrelin hydrogel implant
- **DRUG:** Zoladex goserelin implant

## Key facts

- **NCT ID:** NCT01394263
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2001-12
- **Final completion:** 2003-12
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01394263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01394263, "Study of Histrelin Subdermal Implant in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01394263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*